This is for investors, business and research leaders interested in Antibody technologies and strategies, and hearing from their peers.About this Event
Antibody technologies are at the forefront of therapeutic innovation, particularly in the battle against various diseases, including cancer, autoimmune disorders, and infectious diseases. One of the latest trends is the development of bispecific antibodies. These antibodies are engineered to bind two different antigens simultaneously, enhancing their efficacy in targeting multiple pathways and improving therapeutic outcomes. This capability is particularly valuable in cancer treatment, where bispecific antibodies can redirect immune cells toward tumor cells, thereby promoting a more robust immune response.
Another significant trend is the use of monoclonal antibodies (mAbs), which have gained traction due to their specificity and reduced side effects compared to traditional treatments. Companies are increasingly focusing on mAbs that can be combined with other therapies, such as checkpoint inhibitors, to maximize their effectiveness. This combination therapy approach has shown promising results in clinical settings, leading to higher response rates in patients.
Moreover, antibody-drug conjugates (ADCs) represent a cutting-edge strategy where mAbs are linked to cytotoxic drugs. This targeted delivery system allows for precise treatment of tumors while minimizing damage to surrounding healthy tissues. The FDA has approved several ADCs in recent years, indicating a growing acceptance of this innovative approach in oncology.
In parallel, the emergence of personalized medicine is shaping antibody therapies. As genomic and proteomic profiling becomes more advanced, therapies can be tailored to target specific patient populations based on their unique molecular characteristics. This precision approach not only enhances treatment efficacy but also improves patient outcomes.
Finally, the integration of artificial intelligence (AI) in antibody design and development is transforming the landscape. AI algorithms can analyze vast datasets to predict antibody affinity and stability, accelerating the discovery and optimization processes.
Overall, the antibody technology landscape is rapidly evolving, driven by innovative strategies and the pursuit of more effective, personalized therapies. In this "think-tank" style event we will share challenges and solutions within this sector with business and research leaders and investors active in the sector.
Keynotes soon to be announced.
How you will benefit from attending Agile Leaders?
As a Business or Research Leader, you will benefit from this "Agile" workshop by sharing common challenges and building deeper connections and trust with your peers. In turn, the aim is to build your confidence when working in areas normally outside your comfort zone, by learning and having discussions with this / your "Agile" peer network. You can speak to people in a similar position about issues you may not have the opportunity to discuss elsewhere. You can discuss your challenges with a view of learning from other people's experiences to help you find a solution or spark an idea. Why let leaders of emerging companies re-invent the wheel to be successful when we can learn from the experiences of others who have faced similar challenges before.
Chatham House Rules apply - "what goes on in the workshop, stays in the workshop - so to speak!" We are planning to write up some of the interesting features of the discussion but won't attribute anyone's comment or view so they can be identified. This is so we feel we can a free and open discussion without the worry about being quoted somewhere.
Our mission is to help you build your innovation enabled healthcare business so it is "fit for purpose," truly innovative and attractive to the global markets. Helping you build solid trustworthy networks with your peer group, and help spread your creative R&D business network nationally and internationally. Our motivation and focus is on helping you build long-term trustworthy business relationships and support you on your journey through our supportive business community.
This workshop is facilitated by Prof Tony Sedgwick, the self-professed www.ThoughtDisruptor.com. Tony has an esteemed career in life sciences in academia and in business, he is a trained pathologist. His accolades include once being the Global Head of Clinical Trials at Roche AG, and he has also been CEO of four life science companies, Chairman of over 10 Companies, and many positions within the academic community. He is also an active psychologist which is helping him develop his "Agile" community group development passion and is a Jiu-Jitsu Grand Master VI. Last year Tony published the book "The Mighty Advisor" which was a number 1 best seller in the Amazon STEM Business Management category.
We will start this Agile Leaders Forum on the 10 November with a 1.30 pm arrival time (with a prompt 2.00 pm start for the discussion). This is in the Cambridge Innovates Glasshouse, whi ch is 1st Floor of Botanic House, 100 Hills Road, Cambridge CB21LQ. It is a 5-10 min walk from Cambridge Train Station with the best parking at the train station too, I've been told.
For this event, we are limiting it to a maximum of 25 Life Science Leaders only. As such, we recommend you book as soon as possible to avoid disappointment.
Our promise to you is our Agile Leaders Forum will be like no other business workshop you have experienced. You will be walking out of the session inspired, educated and more connected.
In summary:
10 am - the majority of participants arrive: coffee & teas, networking
10.30 am Kick off with interview with Jonathan Green, formerly of MedImmune (TBC).
1.00 pm - coffees, teas, snacks and networking
1.30 pm - The interviews with listed keynotes - wider outreach to participants to also "sense and feel" their opinions on the keynotes and what they have heard. What are the most common challenges and solutions amongst participants etc?
3.30 pm - end
FEE = £90 - ALL-INCLUSIVE - LIMITED TO 25 x C-Level Leaders or Research Directors of R&D Innovation companies.
Investors come along for free.
Event Venue
Botanic House, 98-100 Hills Road, Cambridge, United Kingdom
GBP 90.00
